Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer.

ABSTRACT: Curated electronic health records offer valuable insights into real-world outcomes for patients with advanced tumors. We described real-world treatment effectiveness among patients with HR+/HER2- metastatic breast cancer (mBC) and metastatic triple-negative breast cancer (mTNBC) using ConcertAI Patient360™ Breast Cancer dataset. Patients initiating therapies selected based on literature review and data availability in the metastatic setting between January 1, 2016, and November 30, 2021, were included. Real-world response rate (rwRR), progression-free survival (rwPFS), overall survival (rwOS), time-to-next treatment (rwTTNT), and time-to-discontinuation (rwTTD) were assessed. Three HR+/HER2- mBC cohorts included 292 patients treated with palbociclib + fulvestrant, 274 patients treated with

SUBMITTER: Sadetsky N 

PROVIDER: S-EPMC12848001 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature